(Q35166688)

6 August 2017

1 reference

title

Paclitaxel chemotherapy: from empiricism to a mechanism-based formulation strategy (English)

1 reference

6 August 2017

1 reference

1 reference

3

Alex Sparreboom

1 reference

6 August 2017

Charity D Scripture

1

1 reference

6 August 2017

William D Figg

series ordinal

2

1 reference

6 August 2017

publication date

1 June 2005

1 reference

Therapeutics and Clinical Risk Management

6 August 2017

published in

1 reference

6 August 2017

volume

1

1 reference

6 August 2017

issue

2

1 reference

6 August 2017

page(s)

107-114

1 reference

Preclinical evaluation of alternative pharmaceutical delivery vehicles for paclitaxel

6 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1661618

Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusions

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1661618

Drug interactions with the taxanes: clinical implications

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1661618

Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1661618

Progress in the development of alternative pharmaceutical formulations of taxanes

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1661618

Role of formulation vehicles in taxane pharmacology

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1661618

Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1661618

Measurement of fraction unbound paclitaxel in human plasma.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1661618

Inter-relationships of paclitaxel disposition, infusion duration and cremophor EL kinetics in cancer patients

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1661618

Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1661618

Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1661618

Drug interactions with the taxanes

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1661618

Pharmacokinetics of the taxanes

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1661618

Alternative formulations of paclitaxel

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1661618

Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1661618

THE DEVELOPMENT AND CLINICAL UTILITY OF THE TAXANE CLASS OF ANTIMICROTUBULE CHEMOTHERAPY AGENTS

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1661618

Clinical pharmacology of carboplatin administered in combination with paclitaxel

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1661618

Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1661618

Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1661618

An overview of experience with TAXOL (paclitaxel) in the U.S.A.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1661618

Effects of Cremophor EL on distribution of Taxol to serum lipoproteins.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1661618

Taxol: a history of pharmaceutical development and current pharmaceutical concerns

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1661618

Cytochrome P450 3A-mediated human liver microsomal taxol 6 alpha-hydroxylation.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1661618

Clinical pharmacokinetics of paclitaxel

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1661618

Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1661618

Taxol metabolism. Isolation and identification of three major metabolites of taxol in rat bile

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1661618

Sequences of taxol and cisplatin: a phase I and pharmacologic study

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1661618

Taxol: the first of the taxanes, an important new class of antitumor agents.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1661618

Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayer.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1661618

Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1661618

Mechanism-based pharmacokinetic model for paclitaxel

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1661618

Phase I study of paclitaxel in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1661618

Metabolism of taxol by human and rat liver in vitro: a screen for drug interactions and interspecies differences.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1661618

Inhibition of paclitaxel elimination in the isolated perfused rat liver by Cremophor EL

27 September 2018

1 reference

https://api.crossref.org/works/10.2147%2FTCRM.1.2.107.62910

Comparative effects of paclitaxel and docetaxel on the metabolism and pharmacokinetics of epirubicin in breast cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FTCRM.1.2.107.62910

Improved Paclitaxel formulation hints at new chemotherapy approach

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FTCRM.1.2.107.62910

Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FTCRM.1.2.107.62910

Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FTCRM.1.2.107.62910

Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FTCRM.1.2.107.62910

Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FTCRM.1.2.107.62910

The influence of Cremophor EL on the cell cycle effects of paclitaxel (Taxol) in human tumor cell lines

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FTCRM.1.2.107.62910

The pharmacokinetics of a 1-h paclitaxel infusion

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FTCRM.1.2.107.62910

Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FTCRM.1.2.107.62910

Tissue distribution, metabolism and excretion of paclitaxel in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FTCRM.1.2.107.62910

Preliminary evaluation of a multicenter, randomized comparative study of TAXOL (paclitaxel) dose and infusion length in platinum-treated ovarian cancer. Canadian-European Taxol Cooperative Trial Group

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FTCRM.1.2.107.62910

Sequence effect of epirubicin and paclitaxel treatment on pharmacokinetics and toxicity

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FTCRM.1.2.107.62910

"Inactive" excipients such as Cremophor can affect in vivo drug disposition

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FTCRM.1.2.107.62910

Hepatic metabolism and biliary excretion of Taxol in rats and humans

31 March 2020

1 reference

12 December 2020

Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8

1 reference

12 December 2020

Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL

1 reference

12 December 2020

Pharmacokinetic models for the saturable distribution of paclitaxel

1 reference

12 December 2020

Taxol metabolism by human liver microsomes: identification of cytochrome P450 isozymes involved in its biotransformation

1 reference

12 December 2020

Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme

1 reference

12 December 2020

10.2147/TCRM.1.2.107.62910

Identifiers

DOI

1 reference

6 August 2017

1 reference

6 August 2017

1 reference